E
Qualigen Therapeutics, Inc.
QLGN
$3.01
-$0.03-0.99%
E
Sell
2/24/2025Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 2/24/2025 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 2/24/2025 due to an increase in the volatility index.
E
Sell
2/6/2025Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 2/6/2025 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 2/6/2025 due to a decline in the volatility index.
E
Sell
1/22/2025Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 1/22/2025 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 1/22/2025 due to an increase in the volatility index.
E
Sell
1/7/2025Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 1/7/2025 due to a decline in the volatility index and total return index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 1/7/2025 due to a decline in the volatility index and total return index.
E
Sell
10/14/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 10/14/2024 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 10/14/2024 due to an increase in the volatility index.
E
Sell
9/26/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 9/26/2024 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 9/26/2024 due to a decline in the volatility index.
E
Sell
9/9/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 9/9/2024 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 9/9/2024 due to an increase in the volatility index.
E
Sell
8/21/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 8/21/2024 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 88.17% from -$783.6 to -$1.47M, and EBIT declined 22.44% from -$1.42M to -$1.74M.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 8/21/2024 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 88.17% from -$783.6 to -$1.47M, and EBIT declined 22.44% from -$1.42M to -$1.74M.
E
Sell
8/16/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 8/16/2024 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 8/16/2024 due to an increase in the volatility index.
E
Sell
7/31/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 7/31/2024 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 7/31/2024 due to a decline in the volatility index.
E
Sell
7/12/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 7/12/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 86.18% from -$5.67M to -$783.6, EBIT increased 37.48% from -$2.27M to -$1.42M, and earnings per share increased from -$0.4696 to -$0.3521.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 7/12/2024 due to an increase in the growth index and volatility index. Operating cash flow increased 86.18% from -$5.67M to -$783.6, EBIT increased 37.48% from -$2.27M to -$1.42M, and earnings per share increased from -$0.4696 to -$0.3521.
E
Sell
4/2/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 4/2/2024 due to a decline in the solvency index and volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 4/2/2024 due to a decline in the solvency index and volatility index.
E
Sell
3/18/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 3/18/2024 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 3/18/2024 due to an increase in the volatility index.
E
Sell
2/29/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 2/29/2024 due to a decline in the volatility index.
E
Sell
2/8/2024Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
E
Sell
1/24/2024Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 1/24/2024 due to a significant decline in the solvency index and volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from E+ on 1/24/2024 due to a significant decline in the solvency index and volatility index.
E
Sell
1/27/2023Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 1/27/2023 due to a decline in the volatility index and total return index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 1/27/2023 due to a decline in the volatility index and total return index.
D
Sell
1/12/2023Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 1/12/2023 due to an increase in the volatility index and total return index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 1/12/2023 due to an increase in the volatility index and total return index.
E
Sell
12/27/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 12/27/2022 due to a decline in the volatility index and total return index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 12/27/2022 due to a decline in the volatility index and total return index.
D
Sell
12/9/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 12/9/2022 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 12/9/2022 due to an increase in the volatility index.
E
Sell
11/22/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 11/22/2022 due to a major decline in the growth index, volatility index and solvency index. The quick ratio declined from 1.85 to 1.48, debt to equity increased from 0.08 to 0.09, and EBIT declined 5.83% from -$4.14M to -$4.38M.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 11/22/2022 due to a major decline in the growth index, volatility index and solvency index. The quick ratio declined from 1.85 to 1.48, debt to equity increased from 0.08 to 0.09, and EBIT declined 5.83% from -$4.14M to -$4.38M.
D
Sell
11/18/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 11/18/2022 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 11/18/2022 due to a decline in the volatility index.
D
Sell
11/3/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 11/3/2022 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 11/3/2022 due to an increase in the volatility index.
D
Sell
10/18/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 10/18/2022 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 10/18/2022 due to a decline in the volatility index.
D
Sell
10/3/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 10/3/2022 due to an increase in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 10/3/2022 due to an increase in the volatility index.
D
Sell
9/16/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 9/16/2022 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 9/16/2022 due to a decline in the volatility index.
D
Sell
8/17/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 8/17/2022 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 98.13% from $722 to $1.43M, EBIT increased 17.32% from -$5.01M to -$4.14M, and earnings per share increased from -$0.1224 to -$0.1124.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 8/17/2022 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 98.13% from $722 to $1.43M, EBIT increased 17.32% from -$5.01M to -$4.14M, and earnings per share increased from -$0.1224 to -$0.1124.
D
Sell
5/16/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 05/16/2022.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 05/13/2022.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 05/04/2022.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 04/21/2022.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0985 to -$0.1937.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0985 to -$0.1937.
D
Sell
11/16/2021Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 11/16/2021 due to a substantial increase in the growth index and solvency index. Operating cash flow increased 54.77% from -$6.7M to -$3.03M, earnings per share increased from -$0.1839 to -$0.1, and EBIT increased 34.98% from -$7.39M to -$4.81M.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from E+ on 11/16/2021 due to a substantial increase in the growth index and solvency index. Operating cash flow increased 54.77% from -$6.7M to -$3.03M, earnings per share increased from -$0.1839 to -$0.1, and EBIT increased 34.98% from -$7.39M to -$4.81M.
E
Sell
11/8/2021Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
10/1/2021Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 10/1/2021 due to an increase in the volatility index and valuation index.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E+ on 10/1/2021 due to an increase in the volatility index and valuation index.
E
Sell
9/15/2021Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 9/15/2021 due to a decline in the volatility index.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E+ from D- on 9/15/2021 due to a decline in the volatility index.
D
Sell
8/18/2021Downgrade
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 8/18/2021 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 222.14% from -$2.08M to -$6.7M, total revenue declined 41.15% from $1.9M to $1.12M, and earnings per share declined from -$0.1304 to -$0.1839.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to D- from D on 8/18/2021 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 222.14% from -$2.08M to -$6.7M, total revenue declined 41.15% from $1.9M to $1.12M, and earnings per share declined from -$0.1304 to -$0.1839.
D
Sell
6/1/2021Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 6/1/2021 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.64 to 2.48, total revenue increased 126.75% from $837.7 to $1.9M, and earnings per share increased from -$0.4098 to -$0.1304.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D from D- on 6/1/2021 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.64 to 2.48, total revenue increased 126.75% from $837.7 to $1.9M, and earnings per share increased from -$0.4098 to -$0.1304.
D
Sell
2/1/2021Upgraded
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E on 02/01/2021.
Qualigen Therapeutics, Inc. (QLGN) was upgraded to D- from E on 02/01/2021.
E
Sell
11/17/2020None
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from U on 11/17/2020.
Qualigen Therapeutics, Inc. (QLGN) was downgraded to E from U on 11/17/2020.
NASDAQ
03/12/2025 3:59PM Eastern
Quotes delayed
